{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:31:17Z","timestamp":1759667477447},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kyowa Kirin Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11523-016-0449-2","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T05:09:58Z","timestamp":1469423398000},"page":"807-814","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase 1 Study of CEP-37250\/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors"],"prefix":"10.1007","volume":"11","author":[{"given":"Monica M.","family":"Mita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Nemunaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juneko","family":"Grilley-Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassil","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Strout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"449_CR1","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-05-3812","volume":"66","author":"LG Durrant","year":"2006","unstructured":"Durrant LG, Harding JS, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res. 2006;66:5901\u20139.","journal-title":"Cancer Res"},{"key":"449_CR2","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466\u201373.","journal-title":"J Biol Chem"},{"key":"449_CR3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"449_CR4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601\u20139.","journal-title":"Oncologist"},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725\u201332.","journal-title":"Oncologist"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-016-0449-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0449-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:05:52Z","timestamp":1498316752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-016-0449-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s11523-016-0449-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]}}}